European shares slide to 3-week lows as healthcare stocks hit; new US tariffs in focus

European equities, led by the pan-European STOXX 600, fell nearly 1% on Friday to a three-week low, extending a three-day losing streak and tracking for a weekly decline. The downturn was primarily driven by investor concerns over escalating U.S. tariffs on multiple trading partners and the impact of President Trump's push for pharmaceutical companies, including Novo Nordisk and Sanofi, to slash drug prices, which sent healthcare stocks down 1.3% and Novo Nordisk plunging 4.2% on a profit warning. This broad market weakness saw Germany's DAX and Denmark's OMXC also decline significantly, though select stocks like Campari and IAG posted gains on strong earnings.

Analysis

European equity markets are under significant pressure, with the pan-European STOXX 600 index falling nearly 1% to a three-week low and declining 4.4% from its Monday peak. The sell-off is driven by a dual-pronged macroeconomic headwind: escalating U.S. trade tariffs and direct regulatory pressure on the pharmaceutical sector. President Trump's announcement of steep new levies on multiple trading partners has injected broad-based uncertainty, contributing to a 1.1% decline in Germany's DAX and a 2.8% drop in Denmark's OMXC to a nearly two-year low. Concurrently, the healthcare sector fell 1.3% after the U.S. administration called on major pharmaceutical companies to cut prescription drug prices, directly impacting stocks like Sanofi, which shed 1%. Novo Nordisk was particularly hard-hit, plunging 4.2% to an almost three-year low, a move amplified by a recent profit warning. Despite the widespread negative sentiment, company-specific fundamentals are creating pockets of strength, exemplified by Campari's 8.6% surge on higher operating profit and IAG's 2.1% gain following better-than-expected earnings.

Key Decisions for Investors

• Investors should exercise caution regarding broad European equity exposure due to the escalating U.S. tariff risk and its demonstrated negative impact on major indices like the DAX.
• Holdings in European pharmaceutical stocks, particularly Novo Nordisk and Sanofi, face significant headline risk and potential margin compression from U.S. drug pricing pressure, warranting a review of exposure to the sector.
• Despite the macroeconomic volatility, positive earnings reports from companies like Campari and IAG are being rewarded, suggesting a focus on stock-specific fundamentals and earnings resilience is prudent.
• The disconnect between the headline's mention of Apple and the article's focus on European markets means investors should treat the information on Apple as inconclusive and seek further clarification before acting.